4 years ago

BiVictriX Raises £7.5 Million in IPO to Accelerate Cancer Therapeutics Development

  • BiVictriX, a UK-based biotechnology company developing next-generation cancer therapeutics, has raised £7.5 million after floating on the London Stock Exchange, giving a market capitalization of £13.2 million

  • The funds will be used to accelerate the company's growth strategy and expedite the development and delivery of its next-generation, highly selective cancer therapeutics

  • BiVictriX was advised by Slater Heelis, a Manchester-based full-service law firm, on its admission to the AIM market.

      • ProblemHealthcare

      "making curative treatments available to all patients diagnosed with some of the most challenging cancers and supporting patients who are currently in urgent need of more effective medicines."

      Solution

      "BiVictriX has developed a proprietary platform and the resulting Bi-Cygni therapeutics are uniquely selective for the specific cancers, potentially enabling higher dosing and more aggressive tumour eradication, while reducing life-threatening treatment-related side effects."

      Covered on